Promising combo may keep rare melanoma at bay
NCT ID NCT07400302
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the immunotherapy drug sintilimab to standard chemotherapy can help prevent a rare type of skin cancer (mucosal melanoma) from coming back after surgery. About 220 adults with PD-L1-positive, completely removed tumors will be randomly assigned to get either the drug combo or chemo alone. The main goal is to see how long people stay cancer-free.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUCOSAL MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The first hospital of Jilin University
RECRUITINGChangchun, Jilin, 130000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an immune checkpoint blocker outperform interferon in keeping mucosal melanoma at bay?
- New drug cocktail targets rare, aggressive melanoma
- Can a vaccine keep melanoma from coming back? large trial tests immune boosters
- New drug KUP-101A enters first human tests for advanced skin cancers
- Triple drug attack on melanoma: new trial hopes to boost surgery success
- New drug duo aims to fight rare melanoma before surgery